<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(11)</volume><submitter>Ogdie A</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA).&lt;h4>Methods&lt;/h4>This retrospective analysis, conducted between January 2000 and January 2019, used data from the FORWARD databank. Adult patients enrolled in the registry with self-reported and physician-confirmed diagnosis of PsA or RA were included if they had completed at least one questionnaire before initiating and within 12 months following initiation of MTX or a TNFi. The primary outcome was to examine the prevalence of side effects with MTX and TNFi within the year following treatment initiation. Multivariate logistic regression analysis was performed to examine the association bet</pubmed_abstract><journal>ACR open rheumatology</journal><pagination>935-941</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9661817</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.</pubmed_title><pmcid>PMC9661817</pmcid><pubmed_authors>Stolshek B</pubmed_authors><pubmed_authors>Michaud K</pubmed_authors><pubmed_authors>Ogdie A</pubmed_authors><pubmed_authors>Maksabedian Hernandez EJ</pubmed_authors><pubmed_authors>Shaw Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.</name><description>&lt;h4>Objective&lt;/h4>To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA).&lt;h4>Methods&lt;/h4>This retrospective analysis, conducted between January 2000 and January 2019, used data from the FORWARD databank. Adult patients enrolled in the registry with self-reported and physician-confirmed diagnosis of PsA or RA were included if they had completed at least one questionnaire before initiating and within 12 months following initiation of MTX or a TNFi. The primary outcome was to examine the prevalence of side effects with MTX and TNFi within the year following treatment initiation. Multivariate logistic regression analysis was performed to examine the association bet</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-22T12:32:58.222Z</modification><creation>2025-04-06T00:19:02.769Z</creation></dates><accession>S-EPMC9661817</accession><cross_references><pubmed>35971643</pubmed><doi>10.1002/acr2.11467</doi></cross_references></HashMap>